Search

everythinglearnresearchcommunity

for

Search:↓

PF-998425 is a new, effective, and non-phototoxic treatment for skin conditions related to androgens.

New treatments targeting androgen receptors show promise for drug-resistant prostate cancer.

FCE 28260 is a stronger and longer-lasting inhibitor of 5α-reductase than finasteride, which may make it a better treatment for certain medical conditions.

CGRP MAbs treatment for migraines may also improve rosacea symptoms, but more research is needed to confirm its effectiveness and safety.

Cimicifuga racemosa extract may help prevent and treat prostate issues by inhibiting 5α-reductase.

Anti-acne medications may work by reducing the activity of a protein involved in acne development.

ARQ-234, a protein designed to treat atopic dermatitis, shows increased effectiveness in early testing.

Some oral medications may help treat central serous chorioretinopathy, especially eplerenone, but more research is needed.

The study created special nanoparticles that effectively deliver an anti-inflammatory drug to treat skin inflammation in psoriasis.

Testosterone reduces knee movement, while flutamide and finasteride increase it.

Changing the C-ring structure in certain compounds can make them better at blocking a specific human enzyme.

New compounds with carborane showed anti-androgen effects similar to flutamide.

PF-05314882 selectively activates androgen receptors without much effect on prostate and may help in prostate cancer treatment and hair loss prevention.

Some cannabinoid derivatives may be more effective than current drugs at targeting proteins relevant to prostate cancer treatment.

The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.

Too much AKR1C3 enzyme causes resistance to finasteride by increasing testosterone.

RU58841, a substance from France, can potentially block the effects of hormones that cause hair loss and excessive hair growth, performing better than a similar substance, cyproterone acetate.

The document confirms the structures of major metabolites of the CRTh2 antagonist Setipiprant and identifies minor metabolites.

Two new compounds can block androgen receptor activity in different ways and may lead to new treatments for androgen-related diseases.

Using 5-α-reductase inhibitors before treatment improves outcomes for patients with metastatic renal cell carcinoma.

Afatinib, neratinib, and zanubrutinib could be effective against KRASG12C-mutant tumors.

Activating liver X receptors can reduce fibrosis by stopping certain immune cells from releasing harmful proteins.

MR antagonists may improve skin health and wound healing, especially in aging.

Certain hydroxycinnamate derivatives may effectively inhibit enzymes linked to hair loss with low toxicity.

Canagliflozin helps overcome progestin resistance in certain endometrial cancer cells.

Fractional radiofrequency effectively and safely improves rosacea symptoms.

TRPA1 and TRPV1 channels don't affect mechanotransduction in rat sinus hair follicles.

Oral difelikefalin significantly reduces itch in notalgia paresthetica.

Certain peptides can prevent hair loss in young rats caused by a cancer drug.

Custom software found that common allergy drugs might have new uses for various conditions and could improve survival in some cancers.